Clinical Trials

90 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06788912 2026-05-26

MK-3475-01E

60 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT07190248 2026-05-26

KANDLELIT-007

675 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07252739 2026-05-26

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

130 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT03715933 2026-05-22

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Phase 1 Recruiting

411 enrolled

Sarcoma

Sarcoma, Sarcoma, Ewing

NCT05061550 2026-05-22

NeoCOAST-2

630 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06305754 2026-05-22

MK-2870-009

520 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06312137 2026-05-22

TroFuse-019

780 enrolled

Phase 3 Active not recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06564844 2026-05-22

TROPION-Lung12

25 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT06627647 2026-05-22

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

878 enrolled

Non-squamous Non-small Cell Lung Cancer

NCT06704724 2026-05-22

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Phase 1 Terminated

30 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06712316 2026-05-22

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Phase 2/3 Recruiting

1,260 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07005102 2026-05-22

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

854 enrolled

Tumor-Agnostic

Neoplasms

NCT06561386 2026-05-20

RELATIVITY1093

1,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07365319 2026-05-20

TeLuRide-008

Phase 2/3 Recruiting

750 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03530397 2026-05-19

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

400 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT05431270 2026-05-19

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phase 1/2 Recruiting

40 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06119581 2026-05-19

SUNRAY-01

1,264 enrolled